Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1400ANCILLARY||SWOG||Ancillary Study to Evaluate Patient and Physician Attitudes; Knowledge; and Expectations Related to Return of Genomic Results in Cancer in the SWOG 1400 (S1400) Clinical Trial||Adult CIRB - Late Phase Emphasis|
|WF-1801||NCORP-Wake Forest University||A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy||Cancer Prevention and Control CIRB||Available to Open|
|ALTE03N1||COG||Key Adverse Events after Childhood Cancer||Pediatric CIRB||Available to Open|
|10264||ETCTN||The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome||Adult CIRB - Early Phase Emphasis||Available to Open|
|10329||ETCTN||Phase I Sequential Trial of Agents Against DNA Repair (STAR)||Adult CIRB - Early Phase Emphasis||Available to Open|
|10015||ETCTN||A Non-Randomized; Open-Label; Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma||Adult CIRB - Early Phase Emphasis||Available to Open|
|S1513||SWOG||Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NWU2015-06-02||CLO-Northwestern University||Immunogenicity of Nonavalent HPV Vaccine Administered Prior To Living Donor Renal Transplantation in Adult Women: A Prospective, Single-Arm, Multi-Center Clinical Trial||Cancer Prevention and Control CIRB||Available to Open|
|A221505||Alliance||Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction||Cancer Prevention and Control CIRB||Available to Open|
|AOST1521||COG||A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate; CDX-011 (Glembatumumab Vedotin; CR011-vcMMAE; IND# 128248; NSC# 763737); in Recurrent or Refractory Osteosarcoma||Pediatric CIRB||Available to Open|